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ABSTRACT 
Study of multiple drug usage is common in chemotherapy.  Many research studies examine the 
effect multiple usage of these anticancer drugs.   The study of these drugs together could help 
clarify the biological effects of agents that affect microtubules.  This could guide future cancer 
treatment for patients especially these with breast cancer, an important public health issue.  The 
main purpose of this paper is to apply and compare methods for examining the combined 
effects of anticancer drugs.  We focus on Paclitaxel and Discodermolide.  While in the process of 
modeling the single drug effect, we noticed that these anticancer drugs may be unable to kill all 
the cells even at high concentration, or that, some subpopulation is far less sensitive:  there may 
be a mixed population of two types of cells with very different sensitivities.  According to this 
description, one population of cell is very sensitive to the drug and the other one is nearly 
resistant to the drug.  This model is difficult to fit.  One approach is to fit the low-concentration 
and high-concentration portion of the dose-response curve separately, and then combine them.  
We constructed a simple method to predict the combined drug effects while adjusting for the 
assumption of mixed cell populations.  We will summarize the commonly used methods for 
evaluating drug combination.  Two models are commonly used as reference models to test the 
drug additive effect, which are dose-additive models and effect-additive models.  For effect-
additive models, we focus on the “mutually exclusive” and “mutually non-exclusive” additive 
effect models, and another additive effect model based on a population log kill mixture model. 
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1.0 INTRODUCTION 
 
1.1 PURPOSE OF STUDY 
One possible cause for super-additivity could be heterogeneity in drug sensitivity.  We 
wish to develop a general statistical method to study for drug interaction while taking into 
account the factors of plateau of drugs or a mixed population of cells that other traditional 
methods may not consider.  
The cell heterogeneity assumption is that within each well of the experiment plate, there 
are four kinds of cell population.  These four populations include, the population of cells that 
are sensitive to both drug A and drug B, the population of cells that are ONLY sensitive to drug 
A or drug B; and the population of cells that is resistant to both drug A and drug B.  The 
proportions that are according to these four cell population are giving labels as PAB , PA , PB , RAB , 
respectively. 
One paper has recognized the importance of issue of cell heterogeneity when one wants 
to estimate the effect of chemotherapy on the tumor cell lines.[1] This heterogeneity may create 
a problem when fitting standard model to estimate the affected fraction.  The dose response 
curve may flatten or even reach a plateau at high dose.  However, we cannot be sure if this 
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plateau is  an experiment artifact or if there truly exists a plateau for drug effect.  The model we 
present here is based on the working assumption that a plateau truly exists.     
Some pairs of drugs may have already been discovered to have a super-additive effect 
when they are combined in chemotherapy. Paclitaxel and Discodermolide would be an example. 
[2] This paper will only focus on Discodermolide and Paclitaxel.  We performed analysis on the 
Paclitaxel and Discodermolide while adjusting for the mixed cell population assumption to 
verify if the apparent non-additivity still holds and construct a model for predicting the 
combined drug effect.   
To develop a simple way to fit this cell heterogeneity assumption, we use two 
approximations; one includes the wells treated with low concentrations; the other indicates the 
wells treated with high concentrations.  The first may reveal the parameters governing a more 
sensitive subpopulation.  The second may reveal parameters governing a less sensitive or even 
resistant subpopulation.   
To evaluate drug additivity, there are two different concepts of additive models; they 
are dose-additive and effect-additive models.  Dose-additivity is the usual benchmark agent if 
want to evaluate “synergism”, using the combination method.   We also examine on effect-
additive model, well-known examples are the mutually exclusive and mutually nonexclusive 
additive models.  By fitting Paclitaxel and Discodermolide with mutually exclusive and 
mutually nonexclusive models, we can check if our models would produce the same result as 
other papers have stated.  In the future, maybe the models we present here can be used to 
understand more about the mechanism of other microtubule perturbing agents, either known or 
unknown.  We will also base our mixed population assumption on effect-additive model.  
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The terminology used in discussion of combination of agents is still ambiguous. 
“Synergism”, “synergy”, and “super-additivity” are used exchangeably, but with multiple 
meanings.  Super-additivity sometimes is called synergism, which is when two drugs work 
together to create an effect that is “greater than expected” (dose super-additivity or effect super-
additivity).  The methodology of how to evaluate the drug effect when they work together is 
developing and there are competitive ways of doing this.  As statisticians, we can evaluate from 
the data if there is more than an additive effect relative for a particular additive model, but the 
data can only suggest, not prove, any mechanistic biological interaction between the drugs.  
Studying combinations of drugs could help to reduce the dose the patients need and possibly 
reduce the side effect of the drugs.  We will be using “dose” and “concentration” 
interchangeably in this paper. 
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2.0 RELEVANT LITERATURE 
 
2.1 THE DRUGS 
 
Anticancer drugs have several working mechanisms to stop the cancer growth.  One of 
the ways is to condense microtubules of cancer cells and stabilize them from deploymerization.  
Paclitaxel and Discodermolide are two examples that work to condense microtubules and 
interrupt the mutated cell from further splitting. [2][4] Paclitaxel is the generic name of Taxol.  
Taxol has been used in ovarian, breast, and non-small lung cancer.  Discodermolide was 
isolated from a marine sponge and reported to induce the assembly of micrutubles in vitro 
more rapidly than Taxol and cause mitotic arrest and microtubule bundling.[2] There are 
several papers that study the combined effect of Paclitaxel and Discodermolide.  Most studies 
use the median-effect method and combination index from Chou and Talalay [3] to determine if 
the agents work together would produce a super-additive effect.  However, they failed to take 
into account other statistical approaches, which to be discussed in the paper.     
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Figure 1 is the graph where you can see how cell division works and METAPHASE is 
the phase where these agents work. 
1
                                                          
1 https://eapbiofield.wikispaces.com/CHAPTER+12+THE+CELL+CYCLE+WH 
 
Figure 1 Cell Cycle 
A study was reported on the effect of three new agents, epothilones, eleutherobin, and 
discodermolide, that were identified, which have similar mechanism with Taxol. [2]   This paper 
was focusing to compare and contrast these new agents in Taxol - sensitive and –resistant cell 
lines. They used Taxol-sensitive cell lines to see if some of these agents can be used as 
substitute for Paclitaxel.  The researchers observed in Taxol- resistant cell line that “the presence 
of Taxol significantly amplified the cytotoxicity of discodermolide, and this phenomenon was 
not observed in combinations of Taxol with either the epothilones or eleutherobin.”  Thus, the 
paper suggested that Taxol and discodermolide may produce a super-additive effect in 
chemotherapy.  The researchers in this paper have considered the assumption of mixed cell 
populations, so they isolated the taxol-resistant cell line for Discodermolide to works on.  
Therefore, heterogeneity of cell population is an important when we wish to evaluate the 
combined drug effect.  
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Another research done at the University of California, Santa Barbara, and Albert 
Einstein College of Medicine, Brownx, New York, demonstrated that Paclitaxel and 
Discodermolide inhibited the growth of lung cancer cells by 41 percent when used together.[5]   
Discodermolide and Paclitaxel works alone only inhibited proliferation the cancer cell by 9.6 
and 16 percent, respectively.  They suggested that Paclitaxel and Discodermolide would 
synergistically block cell cycle progression.  It was known that Paclitaxel and Discodermolide 
have similar mechanism and they are competitive for the same binding site on microtubules, so 
it was surprising to see that these two agents would work together to create super-additive 
effect, quoted by the paper.  
One thing needs to be aware is these conclusion were based by using lung cancer cell 
lines, but the data we have here is using breast cancer cell lines. 
 
 
2.2 THE MODELS FOR SINGLE DRUG 
 
We will give a summary of the models that are used to evaluate the combined drug 
effect.  We start the summary from the single drug models.  We can combine then combined 
these single drug models to study the combined drug effect.  We will also introduce the mixed 
cell population assumption and present how to modify the model for this assumption. 
 
2.2.1 Median-effect model 
 
Median-effect model is derived from the mass-action law and describes the dose-effect 
relationship.    The median-effect equation is  
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𝑓𝑓𝑓𝑓
𝑓𝑓𝑓𝑓
= � 𝐷𝐷
𝐷𝐷𝐷𝐷  �𝐷𝐷    (1) 
where fa is the fraction of the cells that is affected by drug, fu is the fraction of the cells that is 
unaffected, D is the dosage or the concentration of a drug, Dm  is the median-effect dose, and m 
is the slope of median-effect plot that signify the shape of dose-effect relationship, and m<1, =1, 
and >1 indicate flat sigmoidal, hyberbolic, and sigmoidal dose-effect curves.     Median-effect 
plot is an important step for plotting the combination index plot, because we can drive the 
value of m and Dm from this particular plot and plug these values into the equation of 
combination index. [3][6][7][8] 
The median effect equation can be transformed to  
    log10(fafu ) = mlog10(D) – mlog10(Dm )            (2)  
which follows the classic straight line equation y= m*x+ b,  where m is the slope of the median 
effect plot, and b is the y-intercept.    
 
2.2.2 Log(kill) model 
 
The log(kill) model assumes fu=10−kd                   (3)  
, where fu is the fraction of cell unaffected by the drug, d is the dose of the drug, and k is the 
killing rate of drug based on power of 10.  As the dose increases, the fraction of cells unaffected 
would decrease.  We name this equation as log(kill) model.   
 
 
 
8 
 
2.2.3 Heterogeneity model 
 
However, after some analysis, we discover that maybe there are just a mixed population 
of cancer cells one portion is very sensitive to drug and the other part is nearly resistant to the 
drug.  This is the concept we want to focus on in this paper. 
We suggest that heterogeneity of cells is an important concept to consider when we 
want to evaluate the drugs effect.  It needs to be aware that the cell population we label as 
resistant to the drug does not mean they are 100% resistant to the drugs, but they appears 
resistant to the dose range that we have.  Perhaps, ff the dose increases to infinitely large, all the 
cells can still be killed. 
We alter the log(kill) model to this assumption  
Z(dD )avg .# of  control  cells = (PS +  PD)θD(1)dD +  (1 − ( PS + PD)) θD(2)dD   
 = ψDθD(1)dD + (1 − ψD)θD(2)dD    (4)  
where  Z(dD) is the cell count corresponds to different dose of drug and D indicates which drug 
is used.  ψD  = PS + PD,  PS  is the population proportion of cells that are sensitive to both of drugs 
and PD is the population proportion of cells that are sensitive to only one of the drugs.  θD(1)dD =
�e−KD 1�dD is the proportion of cells that are highly sensitive to the drug D even when the drug 
increase in small scale, and θD(2)dD = (e−KD 2 )dD  represents the second portion of cells that react 
slowly to the drug, which is at end of high level of concentration. 
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2.3 THE MODELS FOR COMBINED DRUGS 
 
There are two primary classes of additive models used as references when evaluating 
the combined effects of drugs: dose additivity and effect additivity. 
 
2.3.1 Dose Additivity  
 
In a dose additive model, the two drugs act as if they are equivalent up to a dose 
conversion factor, or potency ratio, K. If K is equal to one, then two drugs are equally potent.  If 
K is not equal one, then one drug can be treated as a more concentrated or more diluted form of 
the other drug.  Then the combined effect is given by  
 
e(𝑑𝑑1,𝑑𝑑2) = 𝑒𝑒(𝑑𝑑1 +  𝑘𝑘𝑑𝑑2, 0) = 𝑒𝑒(0,𝑘𝑘−1𝑑𝑑1 + 𝑑𝑑2). (5) 
 
 In the dose additive model, the transformation of effect is not important.  However, 
thechoice of effect transformation is important for the error model.  It is assumed that the dose 
is untransformed.   
 
2.3.2 Combination Index (CI) Analysis  
 
 Combination index is frequently used to describe deviations from dose additivity 
between two drugs.  Combination-Index was developed in 1983 by Chou and Talalay for 
comparing data to a dose additive model assuming median effect single drug models.[3][6][7]  
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            CI = (𝐷𝐷)1(𝐷𝐷𝑋𝑋 )1 + (𝐷𝐷)2(𝐷𝐷𝑋𝑋 )2 = (𝐷𝐷)1(𝐷𝐷𝐷𝐷 )1� 𝑓𝑓𝑓𝑓1−𝑓𝑓𝑓𝑓 � 1𝐷𝐷1 +  (𝐷𝐷)2(𝐷𝐷𝐷𝐷 )2� 𝑓𝑓𝑓𝑓1−𝑓𝑓𝑓𝑓 � 1𝐷𝐷2   (6)  
 
where (D)1 and (D)2 indicates the dosage of drug 1 and drug 2 respectively.  (𝐷𝐷𝑋𝑋)1 and (𝐷𝐷𝑋𝑋)2 is 
the dose of drug 1 or drug 2 that inhibit x% of cell growth.  fa  is the fraction of cell that is killed 
by the drugs.  F1−1 �fafu� = (DX)1  and F2−1 �fafu� = (DX)2 , where F1  and F2  are dose response 
curves.  Dm is the dose that is required to reach the median effect and can be calculated from 
the median-effect equation (2) as 
   
                Dm = 10−bm   (7)  
           
where m is the slope of the median effect plot, and b is the intercept (constant term). 
CI <1, =1, and >1 are sometimes interpreted as synergism, additivity, and antagonism, 
respectively.   [3][6][7][8]  Chou and Talalay combines the single drug median-effect model 
estimation for F1 and F2 with Equation (6).[3][6][7][8] 
In order to plot the CI, we can to first fit the median-effect models for each drug to 
estimate Dm and m value for each drug.  Next, plug these values into the CI equation (6), to get 
the CI value for different dose combinations. 
Equation (6) is not limited to use the median effect dose to find the CI value.  The CI can 
be interpreted as follows.   
According to the dose-additivity model, we can construct parallel lines for different 
values of effects, fa .  Suppose x% effect can be reached for drug 1 and drug 2 alone, with (𝐷𝐷𝑋𝑋)1   
and (𝐷𝐷𝑋𝑋)2  .  However, x% is reached with d1 and d2, that is the point CI(d1, d2) in Figure 2., 
11 
 
instead of our expected doses, and assume we know the potency, k, between drug 1 and drug 2.  
Use d1, d2 , and k, we can reconstruct the dose-effect line that d1 and d2  should have 
corresponded to, for example y%, which should parallel to the dose-effect line of x%.  We can 
then calculate the single drug doses that are expected to reach y%.  For example, (𝑑𝑑𝑦𝑦)1 = d2*k + d1.   If we divided (𝑑𝑑𝑦𝑦)1by (𝐷𝐷𝑋𝑋)1, this will reproduce the equation (6) and this will be the CI 
value.   
                  CI = (𝑑𝑑𝑦𝑦 )1(𝐷𝐷𝑋𝑋 )1 = (𝑑𝑑𝑦𝑦 )2(𝐷𝐷𝑋𝑋 )2   (8) 
If lines are parallel.  
It is important to know that to be able to interpret the CI value this way is valid when m1, m2 in Equation (6) are equal. Different values of m change the sigmoid shape of the median 
effect line and the isoboles will not be parallel with each other.  If the isoboles are not parallel 
with each other, Equation (8) is no longer true. 
 
Figure 2 Isobole 
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2.3.3 Effect additivity   
 
In an effect-additive model, given the effect of each drug, when the two drugs are 
combined, the predicted effect is the sum of two single drugs’ effects relative to the chosen sacle.   
 
f(e(𝑑𝑑1,𝑑𝑑2)) = 𝑓𝑓(𝑒𝑒(𝑑𝑑1, 0)) + 𝑓𝑓(𝑒𝑒(0,𝑑𝑑2))  (9) 
 
where e is the effect of the drug measured as the fraction of cells killed. 
Transformation of effect is crucial because whether effect-additivity holds depends on 
the scale on which the effect is measured.   
If there is an effect greater than the expected, then there exists a super-additivity effect.   
 
             f(e(𝑑𝑑1,𝑑𝑑2)) > 𝑓𝑓(𝑒𝑒(𝑑𝑑1, 0)) + 𝑓𝑓(𝑒𝑒(0,𝑑𝑑2)).                                                          (10) 
 
2.3.4 Effect-additivity: mutually exclusive 
 
 In statistical definition, “mutually exclusive events are two or more events for which the 
occurrence of one event precludes the occurrence of the others” [9].  In equation form it will 
simply be e=e1+e2, no interaction term involves.  In pharmacology, mutually exclusive drugs 
are two drugs that have the same or similar modes of action. [2]   Since two drugs have the 
same mechanism and they are competitive with each other for the same working site, two drugs 
cannot work simultaneously on the same working site.  Due to the law of mass action, this takes 
an altered form.   
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The effect-additive equation for the mutually exclusive model is  
                𝑒𝑒1−𝑒𝑒 = � 𝑒𝑒11−𝑒𝑒1� +  � 𝑒𝑒21−𝑒𝑒2�  (11) 
where e= effect of the drugs.  𝑒𝑒1, 𝑒𝑒2 are effect for drug 1 and drug 2 alone.  This equation is 
equivalent to Equation (9) with transformation f(e)=  𝑒𝑒1−𝑒𝑒 . 
Research has shown that Discodermolide is competitive with Paclitaxel for microtubule 
binding and Discodermolide has higher affinity, so Discodermolide and Paliclitaxel might fit a 
mutually exclusive model. [4][5] 
 
2.3.5 Effect-additivity: mutually nonexclusive 
 
Alternatively, mutually non-exclusive drugs mean two drugs are non-competitive.  For 
the mutually nonexclusive model 
                �1 − 𝑒𝑒1−𝑒𝑒� = �1 − 𝑒𝑒11−𝑒𝑒1� ∗  �1 − 𝑒𝑒21−𝑒𝑒2�  (12) 
Subtracted one from the left side and the most right side and multiple by -1.  Then 
                  𝑒𝑒1−𝑒𝑒 =  𝑒𝑒11−𝑒𝑒1 + 𝑒𝑒21−𝑒𝑒2 − � 𝑒𝑒11−𝑒𝑒1� ∗ � 𝑒𝑒21−𝑒𝑒2� (13) 
where e is the effect. 
and this equation is equivalent to Equation (9) with different transformation, which is 
f(e)=log(1 − 𝑒𝑒1−𝑒𝑒). 
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From the view point of a mutually exclusive model, this looks as though there is an 
interaction term, which is the product of the previous two terms, times -1, suggesting inhibition.  
This shows how crucial the choice of effect scale is.  
This concept is similar, but not identical to statistical independence of two events.  
If the two events, “cell survives drug 1” and “cell survives drug 2”, are independent 
P(a cell would survive if under treatment with drug 1 AND drug 2) 
=P(a cell would survive under drug 1 only)*P(a cell would survive under drug 2 only). 
The model can be written as 
 
f(e12) = f(e1) + f(e2), where f(ed)= log(1 – e) (14) 
 
where d=1 or 2, indicates which drug is used. 
 
2.3.6 Effect-additivity: Heterogeneity of cell population  
 
The models that we have discussed so far require that for as the dose goes to infinite 
large, the cell count approaches zero.  The data seems to contract this behavior.  This leads us to 
the assumption of mixed cell populations. 
Even within the same cell lines, the cells treated are not likely to be homogeneous with 
respect to cytotoxicity.  There may be some portion of the cell populations that each drug is 
unable to kill. However, it does not mean this proportion of cell populations cannot be killed 
because other kinds of drugs may have the ability to kill this portion of cell population due to 
different biological components or functions.  The fraction of cells that is sensitive to drug D but 
not to the other drug is the probability of cell population that is only sensitive to this drug, so it 
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is called PD  = P (sensitive to drug D), where D indicates drug A or drug B.  Furthermore, the 
probability of a cell belonging to the cell population sensitive to both drugs A and B would be PAB  = P (sensitive to both drug A and B).  Vice versa, a cell population that is resistant to both 
drugs would be labeled as RAB  = P(resistant to both drug A and B).  
Table 1. Heterogeneity of cell population 
P(Sensitive to A, Sensitive to B) 
= 𝑷𝑷𝑺𝑺 P(Sensitive to A, Resistant to B) = 𝑷𝑷𝑨𝑨 P(sensitive to A)  = 𝚿𝚿𝑨𝑨= 𝐏𝐏𝐒𝐒 + 𝐏𝐏𝐁𝐁 
P(Resistant to A, Sensitive to B) 
= 𝑷𝑷𝑩𝑩 P(Resistant to A, Resistant to B)  =𝑹𝑹𝐴𝐴𝐴𝐴  P(Resistant to A) 
P(Sensitive to B)= 𝚿𝚿𝑩𝑩=𝐏𝐏𝐒𝐒 +  𝐏𝐏𝐁𝐁 P(Resistant to B) =100% 
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3.0 METHODOLOGY 
 
 
The experiment was performed in purpose to test the additive effect within the anti-
cancer agents.  There are four different anti-cancer agents that were being tested in this data; 
they are Vincristine(Vinc), , Disorazole C1(Diso) , Paclitaxel, and Discodermolide(Disco).   We 
want to confirm the existing proven case of super-additve effect between Discodermolide and 
Paclitaxel.  
 
 
3.1 DATA COLLECTION 
 
The data is from Dr. Vogt, who is the associate director of Fiske Drug Discovery 
Laboratory of University of Pittsburgh Drug Discovery Institute.  The experiments initially were 
performed for wishing to evaluate the effect between Disorazole C1, the novel anticancer agent, 
with other anticancer agents, such as Taxel and Vincristine here. 
The experiments were performed as follow: 
1. On Day 0, plate 1,000 MDA-MB-231 breast cancer cells in plates and separate them into 
control (non-treated) and case (treated) cells.  There are 24 columns and 16 rows, which 
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adds up to 384 wells, in each plate.  Among these 384 wells, there are 96 combinations of 
different drugs or at different concentration and each combination or concentration has 
four replications.  Also, there are four columns of controls in each plate.   
2. Stain the nuclei within cells with fluorescent DNA-binding dye, Hoechst 33342.   
3. Treat cells with compounds in 10 two-fold serial dilutions starting at highest 
concentration.  
4.  Incubate cells for 72 hours at 37C, 5% CO2. 
5. On Day 4, enumerate the cell number and determine cell density, which is cells per 
image field, by automated image acquisition and batch image analysis on the ArrayScan 
II.   
6. Calculate growth inhibitory activity as percent cell survival compared to control based 
on cell expansion over the duration of the study.   
The ratio between two drugs is being kept constant by automated a serial dilution.  
The measurement of drug effect, which is cells affected fraction in this data, is within the range 
of 0 to 1.   
Fraction = 1 – Treated  CellsControls  (Untreated  Cells ) (15) 
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Figure 3 Different experiments have different combinations of drugs.  We will only focus on analyzing Paclitaxel and 
Discodermolide. 
The pair we focus on is Discodermolide versus Paclitaxel from RPS-118.  The concentrations 
were as follows  
Table 2. RPS-118 Discodermolide vs. Paclitaxel 
 Paclitaxel (µM) Discodermolide(µM) at 
1:5  
Discodermolide(µM) at 
1:2 
1 50 250 100 
2 25 125 50 
3 12.5 62.5 25 
4 6.25 31.25 12.5 
5 3.125 15.625 6.25 
6 1.5625 7.8125 3.125 
7 0.78125 3.90625 1.5625 
8 0.390625 1.953125 0.78125 
9 0.195313 0.976563 0.390625 
10 0.097656 0.488281 0.195313 
 
In RPS-118, the drug combinations are Disorazole C1 versus Paclitaxel at 2:1, Disorazole 
C1 versus Vincristine at 1:1, and Discodermolide versus Paclitaxel at 2:1 and 5:1.  There is a 
plate 
First, the data is reorganized in Excel to be suitable for SAS to read and use.  The data 
used here is the cell survival count per field in the wells. There are 384 wells within each 
experiment plates.  Among these 384 wells, 64 of them are control wells and the rest 320 wells 
Discodermolide
(Stabilizer)
Paclitaxel
(Stabilizer)
RPS-109
RPS-118
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are treated with different concentrations of drugs.  There are 10 concentrations of each drug 
alone and 10 concentration combinations of each drug pair.  There are four replications for each 
concentration combinations and we treat each replication as an independent experiment output.  
We choose to exam our methods on RPS-118 because the controls in RPS-118 do not have any 
particular systematic error and it is easier for us to explain the outcome bases on such controls.  
APPENDIX Table 1A is the plate layout. 
 
3.2 DATA QUALITY ISSUES 
 
 
One thing to be kept in mind is that we are not sure all these survival cell counts 
scanned by the machine truly count only living cells.  We know the nuclei of cell are stained 
with fluorescence, but we are not sure if the scanner would definitely only pick up the viable 
cells.  Or it could be that a plate was not clean enough, so there was some unknown chemical 
left on the plate.  Therefore, what we present here is based on the assumption that these cell 
counts truly count only living cells. 
 
3.2.1 Data Recording 
 
The data we used here must be handling with care because the experiments had several 
problems which appeared when we examined the data.  The data we initially received was in 
terms of a calculated unaffected fraction ( fu ) , rather than the original count data.  The 
unaffected fraction that is above one had been deleted from the data, because affected fraction 
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(fa) = 1 - fu  will become negative, and calculating CI value cannot include such data.    This 
could cause systematic error in model estimated.  Thus, we requested the raw data, the cell 
counts that were recorded for each well, including controls, 394 wells for each experiment plate. 
 
3.2.2 Outliers 
 
Over-dispersion and outliers are two issues to consider when we want to fit the model 
appropriately.  For the Poisson distribution, the mean is equal to the variance.  Outliers could 
influence the model fit if the variance greatly exceeds the mean.  Outliers can be easily detected 
when we draw the residual plot.  When there are outliers, we should be aware that our model 
fits may be influenced by these outliers and we should be really careful on making conclusion 
based on such model.  One thing we could do is to delete the outliers and fit the model again, 
this way the model would be less biased.  However, deleting outliers is not always the best as 
this may create other bias problem. 
3.2.3 Systematic Errors 
 
We wish to consider other factors that may influence the cell count besides the drugs.  
We will examine the systematic errors only on the control wells because we can rule out the 
effect of drugs and it will be easier to detect if there are other factors that would influence the 
cell counts.  The concentrations were not randomly placed on the plate, so row and column may 
be two factors needed to be considered besides any biological effect of the drugs.  We fitted only 
the counts from control wells with only row and column number and treated row and column 
number as numeric parameters, not as categorical parameters.  Cell counts can be assumed 
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initially to have the Poisson distribution.  The results from SAS show linear row effect is highly 
statistical significant and they should be considered when we want to fit the model.  We can see 
from Figure 4 and Figure 5 that there is an increasing row effect, but there is no particular trend 
that suggests column effect. Ideally we should control for the row effect in each model.  This has 
not yet been done. 
 
 
Figure 4. Control wells show increasing row effect 
 
 
 
Figure 5.  Control wells do not show column effect 
 
 
3.2.4 Baseline Effect 
 
We do not know how many cells are in each well before we apply our treatments.  It 
would be difficult to keep the number of cells fixed in each well.  The survival cell counts in 
control wells were expected to be random, and drawn from the same distribution as the 
unknown initial counts in the treated wells.   Therefore, this should be added to the model as a 
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random variable when we estimate the model.  To simplify the model fitting process, we fixed 
the baseline control value by calculating the average of all control wells.  
  
                                                             3.3 Fitting Single Drug Effect  
 
Interaction can be defined in several ways when it comes to drugs.  By Chou and Talalay, 
when one drug interferes with another drug’s working pathway, it is sometimes called an 
interaction.  Also, when one drug can improve another drug’ working pathway, it is sometimes 
called a synergism effect.  We will focus on the drug pair of Paclitaxel and Discodermolide to 
illustrate our method. 
When one wants to evaluate if the model is a good fit to the data, people usually would 
plot the residual plot of the model to check model fit and see if any outlier exists.  If the residual 
plot has any particular pattern or trend, the model may not be a good fit for the data.    If the 
points are scattered around randomly around 0, the model may be acceptable.  If there is point 
that has a large residual and locates far away from most of other points, then this point could 
possibly be an outlier.  We will plot the residual plots to help us determine if the model is a 
good fit. 
 
3.3.1  Median-Effect Model 
 
One of the important features of median-effect plot is to flatten the sigmoidal curve in 
the dose-effect plot by taking log of both side of the median-effect Equation (1).  Then we 
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compare the median-effect model to the data by taking logarithm of concentration and  fafu .  The 
plot would have y-axis as logit (fa) and x-axis as log(dose). 
The median effect model is fitted by PROC REG for least squares on the logit scale of fa .  
The linear regression fitted will be in the form of equation (2). 
 
3.3.2 Log(kill) Model  
 
The log(kill) model can be plot with log (based 10) for fraction unaffected on the y-axis 
and the dose of drug but (not logged) on x-axis.  The model is fitted by least square on the scale 
of log( based 10) for fraction unaffected by using PROC REG. 
 
3.3.3 Log(kill) Mixture Model 
 
We plot the effect, the cell count divided the average of control wells, of each drug 
against the dose.  This heterogeneity assumption will lead to different effect-additive model 
because the proportion populations are varied to each drug. 
This outcome is a fraction, the cell count of the treated well divided by the average of 
four control columns.  Then to separate equation (4) into two portions that one corresponds to 
low concentration of drug and the other portion corresponds to high concentration of drug. 
According to our mixed population assumption, the sensitive and resistant cells should 
have different survival rate.  Therefore, we should assign the appropriate survival rate for these 
two populations instead of fitting all together with only one survival rate, K.  We separated 
Equation (4) into two parts with two set of concentration ranges. 
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First, let the concentration of drug approach zero and use the fact that e−α ≈ 1 − α , so 
Equation (4) will transform to  
             Z(dD )avg .# of  control  wells ≈ ψD  (1− K1dD) + (1 −  ψD)(1 − K2dD)    
                                               = 1 −  dD(ψDK1 +  (1 − ψD)K2)                             low concentration (16) 
As for the high concentration of drug, let the concentration of drug be very large; Equation (4) 
transform to 
                Z(dD )avg .# of  control  wells ≈ (1 −  ψD)θD(2)dD                high concentration (17) 
After derive the equations for high and low dose, we now would need to determine the 
range of dose for each equation of each drug, which are Paclitaxel and Discodermolide.   We fit 
two analysis models to Equation (16) and Equation (17) with PROC GENMOD, but with 
different details.  For equation (16), the model is assumed to be Poisson distribution with 
identity link function and intercept sets to be 1.  From this analysis, the parameter estimate of 
slope would be (ψDK1 +  (1 − ψD)K2).  As for equation (17), the error model is still assumed to 
be Poisson distribution, but instead of identity link function, log link function is used here.  So 
equation (17) will be  
                log � Z(dD )avg .# of  control  wells � ≈ log(1 −𝜓𝜓𝐷𝐷) −  K2dD    (18) 
The parameter estimated fit by equation (18) will be K2 and the intercept will estimate log(1 − 𝜓𝜓𝐷𝐷) , from which we can derive 𝜓𝜓𝐷𝐷.  Then we can plug K2 and 𝜓𝜓𝐷𝐷 into the slope we 
derived from equation (16) to estimate K1.   
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3.4 FITTING COMBINATION EFFECT 
 
 
3.4.1 Combination Index Model 
 
We mentioned earlier in the paper that m1, m2 in Equation (6) needs to be the same in 
order for the CI to be clearly interpreted.  Therefore, we fit the both single-drug dose responses 
at the same time with an altered form of Equation (2) and we can force the m to be the same for 
both drugs.                log10(fafu ) = mlog10(D) – mlog10(Dm )A + k ∗ 𝑍𝑍 = b + mlog10(D) + k ∗ 𝑍𝑍 (19) 
 
where b= −mlog10(Dm )A , and if it is drug A, Z=0, if it is drug B, Z=1, and k is the coefficient 
parameter for the indicator I. 
The equation for calculating median dose for drug A, (Dm )A , would be the same as Equation (7).  (Dm )A = 10−bm .   However, the equation for drug B would be somewhat different than Equation 
(7), (Dm )B = 10−(b +k)m .  We would fit Equation (19) with least square on the logit scale of fa and 
the estimate slope would be m.  We can use (Dm )A  and (Dm )B  to fit Equation (6) and calculate 
the combination index values, and we can also plot the isobole similar to Figure 2.  Once we 
have estimated (Dm )A  and (Dm )B , we can also calculate the potency between drug A and drug B, 
which would be (Dm )A  (Dm )B =  10 km   
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3.4.2 Mutually Exclusive Model 
 
The other purpose of this paper is to fit the data with our models and to hope we can 
gain a little information about the drugs’ working mechanism.  We know Paclitaxel and 
Discodermolide is a mutually exclusive drug pair.[5]  We fit the data with Equation (11) and 
check if the model fits the data. 
In RPS-118, the combined effect is measured at a 2:1 ratio of concentration of 
Discodermolide to Paclitaxel.  Since the data we have are counts, we divided all the cell counts 
by average number of all 64 control wells, which will be fu.  To calculate fa, fa=1-fu.  In 
Equation (11), we need the ratio, fafu .  We estimated combined drug ratio and single drug ratios 
for both drugs.  To check if the model fits the data well, we plotted the observed ratio against 
the predicted ratios. 
  
3.4.3 Mutually Nonexclusive Model 
 
In addition to the mutually exclusive model, we proceeded to fit the mutually 
nonexclusive model, Equation (12) and Equation (13).  We were interested to see if one of the 
two models, mutually exclusive model or mutually nonexclusive model, would fit much better 
than the other. 
  
3.4.4  Heterogeneity 
 
Previously in the paper, we presented Equation (4), which is for a single drug.  In 
Equation (4), we have three unknown parameters, K1, K2, and ψ .  By fitting low and high 
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equation (16) and (18), we estimated K1, K2, and ψ.  Now, we combined Equation (4) for each 
drug and used the estimates.   
To construct the combined effect model. 
            Z(d1,d2)Avg .# of  control  cells =   
                    PSθA(1)θB(1) + PAθA(1)θB(2) + PBθA(2)θB(1) + (1 − PA − PB − Ps)θA(2)θA(2)  (20) 
where PS  is the population proportion of cells that are sensitive to both of drugs, and PA and PB  
are the population proportion of cells that are sensitive to either drug A or drug B, respectively. 
θA(1)θB(1) = (e−KA 1KB 1 )dA dB  is the proportion of cells that are sensitive to both drugs. θA(1)θB(2) =(e−KA 1KB 2 )dA dB  is the proportion of cells that are sensitive to drug A but not drug B. θA(2)θB(1) =(e−KA 2KB 1 )dA dB  is the proportion of cells that are sensitive to drug B but not drug A. And 
θA(2)θA(2) = (e−KA 2KB 2 )dA dB is the proportion of cells that are resistant to both drug A and drug B. 
In Equation (20), we have three unknown parameters, PA , PB , and PS .  However, once we 
find the value for PS , we can easily find the values for PA , PBby Table 1. 
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4.0 RESULTS/ FINDINGS 
 
 
4.1 SINGLE DRUGS 
 
 
4.1.1 Median-effect model 
The red line is the cell counts and the blue line is the fitted value for median effect model. 
The y-axis is the logit scale of fa . The median-effect axis is 0 which represents that fafu  = 1 and fa+  fu  need to be equal to 1. [6][7]     
 
Figure 6 Median effect for Paclitaxel 
 
Figure 7 Median effect for Discodermolide 
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The median effect plot of Paclitaxel  is roughly a good fit; however, if we look closely, 
the cell counts line could be separated into two parts, the first part from -1 to 0.5 log10(dose)is 
more steep and the second of 0.5 to about 1.8 is more flat.  This seems to correspond to our 
assumption of two kinds of cell populations.    
For Discodermolide, there is a dramatic drop around 0.2 log10(dose) level, which could 
possibly suggest a sensitive cell population exist within and correspond to our assumption of 
heterogeneity cell population.  
We also plotted the residual plot to see if the median-effect model fits the data well 
enough.  In Figure 6 there is an obvious curvature, which indicates the median-effect model is 
not a good fit for Paclitaxel.  As for Discodermolide, the residual points seem to decrease slowly 
for these that is close to 0 residual and there are possible outliers exist at the bottom of the graph.  
Therefore, the median effect model is not a good fit for this data either. 
 
 
Figure 8 Residuals for Paclitaxel Median Effect Model  
 
Figure 9 Residuals for Discodermolide Median Effect 
Model 
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4.1.2 Log(kill) Model 
 
We plotted the log10 ( fu )  on the y-axis and the concentrations of Paclitaxel or 
Discodermolide on the x-axis.  The model we fitted is shown in red, and the cell counts are 
shown in blue.  
 
Figure 10 Log(kill) model for Paclitaxel 
 
Figure 11 Log(kill) model for Discodermolide 
Both log(kill) models suggest that there is a plateau effect of affected effect exist because 
the lines would approaches nonzero high-dose asymptote, which could be the largest effect the 
drug alone can achieve.  However, it may also represent that the dosage we used weren’t large 
enough to kill all the cancer cells.   If somewhat we continuously increase the dosage, we may 
be able to kill all the cancer cells.  The log kill model is very poor fitted, and this could suggest 
heterogeneity. 
 
4.1.3  log(kill) mixture model 
From the single drug graphs, we can see that cell survival decrease dramatically at low 
concentration, but when the concentration increases in large scale the killing rate would slow 
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down and appear to reach a plateau effect.  One question emerges from the single drug graph is 
why the cell would respond dramatically to low concentration drug instead of high 
concentration.  We then propose an assumption that instead of one population of cell which has 
plateau effect, there is a mixed population of two kind of cell that one reacts fast to the drug, 
which would correspond to the portion of drug that is killed by low concentration, and the 
other one is insensitive to the drug, which is the portion of high concentration. 
Figure 12 is the actual drug effect plot against the dose of Paclitaxel, and using this 
graph, we can try to determine the dose ranges for fitting Equation (16) and Equation (18). 
Table 3 and 4 shows how the dose ranges for the low-dose and high-dose 
approximations have selected.  The total number of points included equals the number of doses 
times four replications.  The estimates of slope change every time we re-fit the models with 
more points included.  The standard error of the slope, and the scale parameter indicate 
goodness of fit.  We can use the scale parameter to determine if the model fits the data well 
enough.  If the scale parameter increases, this suggests that adding the data for this extra 
 
Figure 12 Actual drug effect vs. Paclitaxel dose  
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concentration would increase the deviation between predicted values and the actual cell counts 
too much.  
Table 3  Low dose approximation for Paclitaxel 
Highest dose 
included  
# of points 
included  
Estimate of 
Slope 
S.E of slope Scale Parameter  
0.1953 8 1.1249 0.1332 0.0652 
0.3906 12 1.2155 0.0925 0.1093 
0.7813 16 0.9450 0.0386 0.1297 
1.5625 20 0.5458 0.0286 0.2749 
3.125 24 0.3299 Can’t fit Can’t fit 
 
Table 4  High dose approximation for Paclitaxel 
Lowest 
dose 
included 
# of Points 
included 
Estimate of 
Slope 
S.E of 
slope 
Estimate of 
Intercept 
S.E of 
intercept 
Scale 
Parameter 
25  8 0.0124 0.0052 -2.3780 0.1974 0.0445 
12.5 12 0.0140 0.0031 -2.3074 0.0932 0.0414 
6.25 16 0.0150 0.0025 -2.2728 0.0630 0.0420 
3.125 20 0.0169 0.0025 -2.2083 0.0532 0.0475 
1.5625 24 0.0260 0.0052 -1.9406 0.0859 0.1026 
 
We conclude from these two tables, the range of low dose for Equation (16) is from 
0.0977µM to 0.7813µM. Adding 1.5625µM, the scale parameter increases more than doubles, 
which means this point should not be added to the model.  When tried to include 3.125 µM, the 
model cannot even fit this value.  As for Equation (18), the range of dose should include from 
1.5625µM to 50 µM.  Fitting Equation (18), we would get the estimate of K2 from estimate of 
slope, and 𝜓𝜓𝑝𝑝𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝𝑓𝑓𝑝𝑝𝑒𝑒𝑝𝑝  from estimate of intercept.  K1 , K2 , and ψpacltaxel , and we got 
ψpacltaxel =0.89011, K1 =  1.05958and K2 =0.016895, which seems to fit the plot because it is 
around 0.1 of cells are hard to kill and K1 is supposed to be very large compare to K2 because K1 
corresponds to the proportion of drugs that is very sensitive to the drug and decay very fast. 
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Figure 13 and Figure 14 are predicted effect against actual effect plots for low dose equation (16) 
and high dose equation (18).  The red line is predicted effect and the blue line is the actual effect.  
 
Figure 13 Low dose approximations for Paclitaxel 
 
Figure 14 High dose approximations for Paclitaxel 
 
Figure 15  Predicted effect vs. actual effect for Paclitaxel alone 
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 DISCODERMOLIDE: 
 
Figure 16  Actual drug effect vs. Discodermolide dose 
Applying the same procedures with Discodermolide, first we look at the graph and see 
which dose point may be the boundary point for Equation (16) and Equation (18).  Table 5 is a 
summary table of fitting Equation (16) and from Table 5, we can roughly decide the range of 
low dose equation should be from 0.195 µM to 3.125 µM because after 3.125 µM, the scale 
parameter start to increase.   Table 6 is derived from fitting Equation (18), and we can see the 
dramatic difference in scale parameter when the dose decreases from 25 to 12.5.  Therefore, the 
range of dose to be used in Equation (18) should be from 25 µM to 100 µM.  Figure 22 shows the 
fitted model seems to fit better than before because the predicted effects are close to the 
observed effects. By fitting Equation (16) and (18), we estimate K1, K2, and ψdisco  to be 
0.12342, 0.0138 and 0.74436, respectively. 
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Table 5.  Low dose approximation for Discodermoolide  
Highest Dose 
included 
# of points 
included 
Estimate of 
Slope 
S.E of slope Scale Parameter  
0.3906  8 -0.1074 0.0489 0.0419 
0.7813 12 -0.0645 0.0258 0.0451 
1.5625 16 0.0457 0.0276 0.1011 
3.125 20 0.0963 0.0127 0.1047 
 6.25 24 0.0856 0.0049 0.0996 
12.5 28 0.0547 0.0030 0.1543 
25 32 0.0341 0.0014 0.2167 
50 36 Cannot fit Cannot fit  
 
Table 6.  High dose approximation for Discodermolide  
Lowest 
dose 
included 
# of Points 
included 
Estimate of 
Slope 
S.E of 
slope 
Estimate of 
Intercept 
S.E of 
intercept 
Scale 
Parameter 
50 8 0.0086 0.0014 -1.7844 0.1036 0.0291 
25  12 0.0138 0.0020 -1.3640 0.1084 0.0664 
12.5 16 0.0211 0.0032 -0.8909 0.1203 0.1288 
6.25 20 0.0245 0.0029 -0.7178 0.0842 0.1314 
3.125 24 0.0288 0.0032 -0.5378 0.0724 0.1520 
1.5625 28 0.0338 0.0041 -0.3614 0.0724 0.1942 
0.7813 32 0.0384 0.0047 -0.2244 0.0672 0.2201 
 
 
 
Figure 17 Low dose approximations for Discodermolide 
 
Figure 18 High dose approximations for Discodermolide 
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Figure 19 Predicted effect vs. actual effect for Discodermolide alone 
After several trying to fit the model, finally the model for Paclitaxel seems to work fine 
now.  However, there is still room for the fit for Discodermolide to improve.  Looking at the 
actual effect graph of Discodermolide again, the residuals do not add to zero, suggesting that 
the informal fitting approach taken here should be replaced by a true maximum likelihood 
approach.   
 
4.2 COMBINATION OF DRUGS 
 
4.2.1 Combination Index model 
 We fitted Equation (19), and the estimated m is 0.92156.  The median doses we 
calculated for Paclitaxel and Discodermolide is 0.65811 and 8.28330, respectively.  Using these 
two median doses, we plotted the isobole which has the slope 10− km = 10−−1.013630.92156 = 12.5865.  We 
also plotted the residual plot of fitting Equation (19).  The curvature in residual plot suggests 
possible quadratic function.  We used these median effect doses to calculate combination index.  
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However, our calculated combination index values mostly are greater than 1, which is not what 
we expect for Paclitaxel and Discodermolide.  This may suggest that our model here is not an 
appropriate one to interpret this data, and this may relate to the quadratic function suggests by 
the residual plot.
 
Figure 20. 𝐈𝐈𝐈𝐈𝟓𝟓𝟓𝟓 Isobole. 
 
Figure 21. Residual plot of Equation (19) 
 
4.2.2 Mutually Exclusive Model 
 
Figure 22.  Mutually Exclusive model of  𝐟𝐟𝐚𝐚
𝐟𝐟𝐮𝐮
We plotted the observed ratios, fafu , against the predicted ratios we calculated by using 
Equation (11).  We can see that the predicted values are really close to the observed one because 
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the slope between observed points and predicted points are close to 1.  Therefore, we can 
conclude that our mutually exclusive model can fit the data well here, which can suggest the 
relation between Paclitaxel and Discodermolide might be mutually exclusive. 
 
 
4.2.3 Mutually Nonexclusive Model
 
Figure 23 Mutually nonexclusive model of  𝐟𝐟𝐚𝐚
We fitted the model by using Equation (13).  We plotted the observed affected fraction, fa , 
against predicted effect.  We can see in Figure 23 that the predicted effects are not close to 
observed effects, the predicted values are lower than observed effect.  Therefore, the mutually 
nonexclusive model is not a good fit for our data, and this could suggest that Paclitaxel and 
Discodermolide is not a mutually nonexclusive drug pair. 
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4.3 MIXED POPULATION OF CANCER CELLS 
 
4.3.1 Heterogeneity 
After fitting low and high dose Equations (16) and (18) for each drugs, we estimated the K1, K2, and ψ for each drugs.  Table 7 organized the values. 
 
Table 7.  Table of 𝑲𝑲𝟏𝟏,𝑲𝑲𝟐𝟐,𝜳𝜳𝑫𝑫 
 𝐾𝐾1 𝐾𝐾2 𝛹𝛹𝐷𝐷=𝑃𝑃𝑆𝑆 + 𝑃𝑃𝐷𝐷 
Paclitaxel  1.05958 0.016895 0.89011 
Discodermolide  0.12342 0.0138 0.74436 
 
At this point, we can get a valid range of 𝑃𝑃𝑆𝑆 by using Table 7. From the column of 𝛹𝛹𝐷𝐷, 
we can see that the largest possible value for 𝑃𝑃𝑆𝑆 is 0.74436.  We know all the proportions, 
𝑃𝑃𝑆𝑆 + 𝑃𝑃𝐴𝐴 + 𝑃𝑃𝐴𝐴+𝑅𝑅𝐴𝐴𝐴𝐴, need to add up to 1, and 𝑃𝑃𝑆𝑆 + 𝑃𝑃𝐴𝐴 + 𝑃𝑃𝐴𝐴 < 1.  We can use this inequality 
and derive the lowest possible value for 𝑃𝑃𝑆𝑆.   
𝑃𝑃𝑆𝑆 + 𝑃𝑃𝐴𝐴 + 𝑃𝑃𝐴𝐴 = (𝑃𝑃𝑆𝑆 + 𝑃𝑃𝐴𝐴) + (𝑃𝑃𝑆𝑆 + 𝑃𝑃𝐴𝐴) − 𝑃𝑃𝑆𝑆 = 𝛹𝛹𝐴𝐴 + 𝛹𝛹𝐴𝐴 − 𝑃𝑃𝑆𝑆 = 0.89011 + 0.74436 − 𝑃𝑃𝑆𝑆 < 1 , 
and 𝑃𝑃𝑆𝑆 ≥ 0.63.  We got a range for 𝑃𝑃𝑆𝑆, 0.63 ≤ 𝑃𝑃𝑆𝑆 ≤ 0.74.  Once we know the value of 𝑃𝑃𝑆𝑆, 
we can calculate the rest of proportions using Table 1.   
To find the most likely value of 𝑃𝑃𝑆𝑆, we estimated the likelihood of 𝑃𝑃𝑆𝑆 to find the 
maximum value of 𝑃𝑃𝑆𝑆.  The maximum likelihood of 𝑃𝑃𝑆𝑆 would be the most likely value of 
𝑃𝑃𝑆𝑆.    We calculate the likelihood of 𝑃𝑃𝑆𝑆 assuming the binomial distribution for the error 
model.  The likelihood equation for the binomial distribution is                𝑝𝑝𝑖𝑖 = [𝑟𝑟𝑖𝑖 log(Pi) + (ni − ri) log(1 − Pi)] (21) 
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where i is the number of observations,  ni would be the average cell counts of  control 
wells, which is a fixed number, and ri  would be the number of cells are killed, 
calculated by subtracting each well’s count from average cell counts.   
 
Figure 24 Likelihoods of 𝐏𝐏𝐒𝐒  
Once we calculated all the likelihood value, we noticed the likelihood increase as the 
value of 𝑃𝑃𝑆𝑆 increases.  Therefore, the maximum likelihood value of PS is at 𝑃𝑃𝑆𝑆=0.74.  Put 
𝑃𝑃𝑆𝑆  into Table 1, where A indicates Paclitaxel and B indicates Discodermolide, and we can 
calculate the rest of proportions. 
Table 8. Calculate the proportions 
P(Sensitive to A, Sensitive to B) 
= 𝑷𝑷𝑺𝑺 = 0.74 P(Sensitive to A, Resistant to B) = 𝑷𝑷𝑨𝑨=0.15 P(sensitive to A)  = 𝚿𝚿𝑨𝑨 = 0.89011 
P(Resistant to A, Sensitive to B) 
= 𝑷𝑷𝑩𝑩=0 P(Resistant to A, Resistant to B)  =𝑹𝑹𝐴𝐴𝐴𝐴=0.11 P(Resistant to A) 
P(Sensitive to B)= 𝚿𝚿𝑩𝑩=0.74436 P(Resistant to B) =100% 
 
We got some interesting results from Table 8, which shows 𝑃𝑃𝐴𝐴 , the proportion that 
corresponds to the cell population that is only sensitive to Discodermolide, is equal to 0.  This 
result could suggest that probably the cells that are sensitive only to Discodermolide do not 
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exist in this data.  The cells we observed are killed under treatment of Discodermolide may be 
the cells that are sensitive to both Paclitaxel and Discodermolide.  
We plugged all the calculated values from Table 8 back into Equation (20), and 
calculated the predicted values of effects.  We then plotted the predicted values with the 
observed effect.  The red line is the observed effects and the blue line is the predicted effect.  
 
Figure 25 Predicted effect vs. actual effect for heterogeneity assumption 
We can see in Figure 25 that after we adjusted for the cell heterogeneity assumption, the 
predicted values are much closer to the actual effects.  Therefore, we can conclude that consider 
the cell heterogeneity assumption can help us to improve the prediction of combined drug 
effects.  
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5.0 DISCUSSION 
 
 
As we mention earlier, we cannot be sure if these survival cell counts are really from 
viable cells.  It can be machine’s error or the plate’s problem.  What we assume here is only the 
working assumption, but this assumption may still prove to be true in the future. 
We focused our analysis on the drug pair of Paclitaxel and Discodermolide.  We first 
performed the single drug analysis with median-effect model and log(kill) model.  Their large 
deviations from the actual effects lead us to the mixture of cell population assumption.  We 
noticed that around 10% of cells survive individual drugs and their combination at high 
concentration.  We later hypothesized that there may be a mixture of cell populations that 
consists of a population that is sensitive to both drugs, two populations that are each sensitive 
to only one of the drugs, and a population that is relatively resistant to both drugs.  
We analyzed the combined drug effects focus on using models for effect-additivity and 
log kill models for mixtures.  To avoid difficult optimization problems, we fitted the normalized 
(fa) data to low and high dose range equation separately and plotted them.  Then we combined 
the estimates we derived from low and high dose equations to construct the mixed population 
model.  After adjusting for the mixed cell population, the predicted effects are quite close to the 
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actual effects.  Therefore, we would suggest that considering the cell heterogeneity assumption 
can improve the prediction of drug effects. 
We also fitted the mutually exclusive and mutually nonexclusive models to check if our 
models can tell us the same drug relation other papers have stated.  And our results have 
showing that Paclitaxel and Discodermolide only fitted well in mutually exclusive model, 
which corresponds to other paper have stated.  Thus, our models maybe can be useful for the 
future investigation in combination of microtubule perturbing agents with known and 
unknown mechanisms of action. 
However, several weaknesses of the experiment need to be kept in mind.  The problems 
with baseline of controls, the outliers, and the way data recorded, and the importance of row 
and column factors, should be considered when we want to estimate the data more precisely. 
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6.0 CONCLUSIONS 
 
As other research papers may conclude that it is surprising to see Paclitaxel and 
Discodermolide works together to produce super-additive effect because theoretically they are 
competitive with each other for their similar mechanism and working site, it is not what we try 
to prove here.   To be able to explain how two agents which are supposed to compete with each 
other can produce a super-additive effect requires an extensive and detailed experiment that 
takes into account many other things, such as the specific working sites of agents, different time 
gaps between using drugs on the cell lines, etc., that we do not have here in this experiment. 
The main purpose for this paper is to provide a summary of methods that can be used to 
analyze drug combinations while adjusting for the mixed cell population assumption.  WE want 
to emphasize the importance of this assumption when one wants to understand drug effects.  
Fitting the heterogeneity assumption into our models for predicting the dr drug effects 
improves our prediction.  These methods may be extended for further analysis of other drug 
pairs, such as Disorazole C1 with Paclitaxel, and Vincristine with Paclitaxel, using data which 
we have not yet analyzed.  Also, our models, such mutually exclusive model, may be useful in 
the future when one want to investigate the combination of drugs of either known or unknown 
mechanisms. 
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What we present here is a statistical analysis that cannot prove any biological conclusion 
until further cancer cell experiments are done.  Also, drug “synergism”, whatever that might 
mean, biologically, might not be desirably clinically.  These drugs may combine well against 
cancer cells, but they may also work too well on normal cells and increase damage on human 
body. 
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APPENDIX: TABLE 1A. LAYOUT OF EXPERIMENT PLATE 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
1                                                      C
O
N
TRO
L 
Vinc 100 (µM
) 
Vinc 50 
Vinc 25 
Vinc 12.5 
Vinc 6.25 
Vinc 3.125 
Vinc 1.5625 
Vinc 0.78125 
Vinc 0.390625 
Vinc 0.195313 
                                                     C
O
N
TRO
L 
                                                     C
O
N
TRO
L 
Pacl 50 
Pacl 25 
Pacl 12.5 
Pacl 6.25 
Pacl 3.125 
Pacl 1.5625 
Pacl 0.78125 
Pacl 0.390625 
Pacl 0.195313 
Pacl 0.09765625 
                                                     C
O
N
TRO
L 
2 
3 
4 
5 Diso C1 100 + Pacl 50 
D
iso C1  50 +  Pacl 25 
D
iso C1  125 +  Pacl 
12.5 
D
iso C1 12.5 +  Pacl 
6.25 
D
iso C1  6.25 +  Pacl 
3.125 
D
iso C1  3.125 +  Pacl 
1.5625 
D
iso C1  1.5625 + 
Pacl 0.78125 
D
iso C1  0.78125  + 
Pacl 0.390625 
D
iso C1  0.390625 +  
Pacl 0.195313 
D
iso C1  0.195313 +  
Pacl 0.09765625 
Pacl 50 + D
isco 250 
Pacl 25 + D
isco 125 
Pacl 12.5 + D
isco 
62.5 
Pacl 6.25 + D
isco 
31.25 
Pacl 3.125 + D
isco 
15.625 
Pacl 1.5625 + D
isco 
7.8125 
Pacl 0.78125  + D
isco 
3.90625 
Pacl 0.390625 + 
D
isco 1.953125 
Pacl 0.195313 + 
D
isco 0.9765625 
Pacl 0.09765625 + 
D
isco 0.48828125 
6 
7 
8 
9 Diso C1 100 + V
inc 
100  
D
iso C1 50 + Vinc 50 
D
iso C1 25 + Vinc 25 
D
iso C1 12.5 + Vinc 
12.5 
D
iso C1 6.25 + Vinc 
6.25 
D
iso C1 3.125+ Vinc  
3.125 
D
iso C1 1.5625+ 
Vinc 1.5625 
D
iso C1 0.78125 + 
0.78125100  
D
iso C1 0.390625 
0.390625100  
D
iso C1 0.195313+ 
0.195313100  
Pacl 50 + D
isco 100 
Pacl 25 + D
isco 50 
Pacl 12.5 + D
isco 25 
Pacl 6.25 + D
isco 
12.5 
Pacl 3.125 + D
isco 
12.5 
Pacl 1.5625 + D
isco 
3.125 
Pacl 0.78125  + 
D
isco 1.5625 
Pacl 0.390625 + 
D
isco 0.78125 
Pacl 0.195313 + 
D
isco 0.390625 
Pacl 0.09765625 + 
D
isco 0.195313 
10 
11 
12 
13 Disco 100 
D
isco 50 
D
isco 25 
D
isco 12.5 
D
isco 6.25 
D
isco 3.125 
D
isco 1.5625 
D
isco 0.78125 
D
isco 0.390625 
D
isco 0.195313 
D
iso C1 100  
D
iso C1  50  
D
iso C1  25  
D
iso C1 12.5  
D
iso C1  6.25  
D
iso C1  3.125  
D
iso C1  1.5625  
D
iso C1  0.78125    
D
iso C1  0.390625  
D
iso C1  0.195313   
14 
15 
16 
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